We are live on ! Find out more

Lexicon Pharmaceuticals

LXRX

Market cap $881M

1.98 USD

-0.02

1%

At close Updated Sep 14, 10:18 AM EDT

1 day

-1%

5 days

-10.81%

1 month

-14.66%

3 months

1.02%

6 months

22.98%

Year to date

73.68%

1 year

76.79%

5 years

-55.61%

10 years

-89.48%

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Employees: 81

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 75%

Negative 16.7%

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin.

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. “Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,” said Mike Exton, Ph.D.

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

See News Rankings

Price charts implemented using Lightweight Charts™